Tazeen Ahmad
Stock Analyst at B of A Securities
(3.42)
# 941
Out of 5,135 analysts
218
Total ratings
49.06%
Success rate
3.92%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $246 → $260 | $223.41 | +16.38% | 12 | Jan 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $529 → $462 | $332.61 | +38.90% | 7 | Jan 30, 2026 | |
| BLTE Belite Bio | Initiates: Buy | $195 | $175.84 | +10.90% | 1 | Jan 26, 2026 | |
| APLS Apellis Pharmaceuticals | Upgrades: Buy | $28 | $21.57 | +29.81% | 10 | Jan 21, 2026 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Buy | $627 → $860 | $793.53 | +8.38% | 1 | Jan 7, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $72 → $58 | $20.18 | +187.41% | 7 | Jan 2, 2026 | |
| FULC Fulcrum Therapeutics | Maintains: Underperform | $6 → $7 | $10.66 | -34.33% | 7 | Dec 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $71 → $112 | $84.84 | +32.01% | 1 | Dec 9, 2025 | |
| PHVS Pharvaris | Maintains: Neutral | $27 → $30 | $26.61 | +12.74% | 5 | Dec 4, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Buy | $53 | $46.45 | +14.10% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $104 | $101.16 | +2.81% | 6 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $880 → $887 | $843.55 | +5.15% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $16 | $17.88 | -10.51% | 26 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $76 | $69.17 | +9.87% | 19 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $27 | $22.95 | +17.65% | 16 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $134 | $106.99 | +25.25% | 9 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.58 | +74.67% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $95 | $102.53 | -7.34% | 9 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.95 | +115.83% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $8.96 | -55.36% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $16.64 | -51.91% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $19.28 | +40.04% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $11.45 | +144.54% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $9.48 | +321.94% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $127.76 | +40.11% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $14.99 | +46.76% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $6.79 | -55.82% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $14.30 | +4.90% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $5.04 | +98.41% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.34 | +347.76% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $6.99 | +114.59% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $4.18 | -52.15% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $2.11 | +184.36% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $24.75 | -39.39% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $328.04 | -81.71% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.33 | +1,103.01% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $153.07 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $20.70 | +1,349.28% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.35 | +282.98% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $22.74 | +111.08% | 6 | Oct 10, 2018 |
Ascendis Pharma
Jan 30, 2026
Maintains: Buy
Price Target: $246 → $260
Current: $223.41
Upside: +16.38%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Buy
Price Target: $529 → $462
Current: $332.61
Upside: +38.90%
Belite Bio
Jan 26, 2026
Initiates: Buy
Price Target: $195
Current: $175.84
Upside: +10.90%
Apellis Pharmaceuticals
Jan 21, 2026
Upgrades: Buy
Price Target: $28
Current: $21.57
Upside: +29.81%
Regeneron Pharmaceuticals
Jan 7, 2026
Upgrades: Buy
Price Target: $627 → $860
Current: $793.53
Upside: +8.38%
Ultragenyx Pharmaceutical
Jan 2, 2026
Maintains: Buy
Price Target: $72 → $58
Current: $20.18
Upside: +187.41%
Fulcrum Therapeutics
Dec 9, 2025
Maintains: Underperform
Price Target: $6 → $7
Current: $10.66
Upside: -34.33%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $71 → $112
Current: $84.84
Upside: +32.01%
Pharvaris
Dec 4, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $26.61
Upside: +12.74%
Scholar Rock Holding
Oct 9, 2025
Initiates: Buy
Price Target: $53
Current: $46.45
Upside: +14.10%
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $101.16
Upside: +2.81%
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $843.55
Upside: +5.15%
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $17.88
Upside: -10.51%
Aug 20, 2025
Maintains: Buy
Price Target: $82 → $76
Current: $69.17
Upside: +9.87%
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $27
Current: $22.95
Upside: +17.65%
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $106.99
Upside: +25.25%
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $4.58
Upside: +74.67%
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $102.53
Upside: -7.34%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $6.95
Upside: +115.83%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $8.96
Upside: -55.36%
May 19, 2025
Maintains: Underperform
Price Target: $10 → $8
Current: $16.64
Upside: -51.91%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $19.28
Upside: +40.04%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $11.45
Upside: +144.54%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $9.48
Upside: +321.94%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $127.76
Upside: +40.11%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $14.99
Upside: +46.76%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $6.79
Upside: -55.82%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $14.30
Upside: +4.90%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $5.04
Upside: +98.41%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.34
Upside: +347.76%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $6.99
Upside: +114.59%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $4.18
Upside: -52.15%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $2.11
Upside: +184.36%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $24.75
Upside: -39.39%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $328.04
Upside: -81.71%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.33
Upside: +1,103.01%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $153.07
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $20.70
Upside: +1,349.28%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.35
Upside: +282.98%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $22.74
Upside: +111.08%